302 related articles for article (PubMed ID: 26951615)
21. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation.
Chan PH; Huang D; Hai JJ; Li WH; Yin LX; Chan EW; Wong IC; Lau CP; Chiang CE; Zhu J; Tse HF; Siu CW
Heart Rhythm; 2016 Feb; 13(2):366-73. PubMed ID: 26392326
[TBL] [Abstract][Full Text] [Related]
22. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.
Staerk L; Gislason GH; Lip GY; Fosbøl EL; Hansen ML; Lamberts M; Bonde AN; Torp-Pedersen C; Olesen JB
Europace; 2015 Aug; 17(8):1215-22. PubMed ID: 25995392
[TBL] [Abstract][Full Text] [Related]
23. Dabigatran use in elderly patients with atrial fibrillation.
Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
[TBL] [Abstract][Full Text] [Related]
24. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
[TBL] [Abstract][Full Text] [Related]
25. Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.
Hernandez I; Zhang Y; Brooks MM; Chin PK; Saba S
Stroke; 2017 Jan; 48(1):159-166. PubMed ID: 27909200
[TBL] [Abstract][Full Text] [Related]
26. Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban.
Charlton B; Adeboyeje G; Barron JJ; Grady D; Shin J; Redberg RF
PLoS One; 2018; 13(3):e0193912. PubMed ID: 29590141
[TBL] [Abstract][Full Text] [Related]
27. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
Wang SV; Franklin JM; Glynn RJ; Schneeweiss S; Eddings W; Gagne JJ
BMJ; 2016 May; 353():i2607. PubMed ID: 27221664
[TBL] [Abstract][Full Text] [Related]
28. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy.
Lauffenburger JC; Rhoney DH; Farley JF; Gehi AK; Fang G
Pharmacotherapy; 2015 Jun; 35(6):560-8. PubMed ID: 26044889
[TBL] [Abstract][Full Text] [Related]
29. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
Hart RG; Diener HC; Yang S; Connolly SJ; Wallentin L; Reilly PA; Ezekowitz MD; Yusuf S
Stroke; 2012 Jun; 43(6):1511-7. PubMed ID: 22492518
[TBL] [Abstract][Full Text] [Related]
30. Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review.
Milling TJ; Fromm C; Ganetsky M; Pallin DJ; Cong J; Singer AJ
Ann Emerg Med; 2017 May; 69(5):531-540. PubMed ID: 28196608
[TBL] [Abstract][Full Text] [Related]
31. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
Lee BH; Park JS; Park JH; Park JS; Kwak JJ; Hwang ES; Kim SK; Choi DH; Kim YH; Pak HN
J Cardiovasc Electrophysiol; 2010 May; 21(5):501-7. PubMed ID: 20021521
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal bleeding risk of non-vitamin K oral anticoagulants is similar to warfarin - a Japanese retrospective cohort study
.
Shirai T; Yamamoto T; Kawasugi K; Kuyama Y; Kita H
Int J Clin Pharmacol Ther; 2016 Nov; 54(11):841-846. PubMed ID: 27569738
[TBL] [Abstract][Full Text] [Related]
33. Advances in Antiplatelet and Anticoagulant Therapies for NSTE-ACS.
Badjatiya A; Rao SV
Curr Cardiol Rep; 2019 Jan; 21(1):3. PubMed ID: 30637536
[TBL] [Abstract][Full Text] [Related]
34. Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients.
Smythe MA; Forman MJ; Bertran EA; Hoffman JL; Priziola JL; Koerber JM
J Thromb Thrombolysis; 2015 Oct; 40(3):280-7. PubMed ID: 25851800
[TBL] [Abstract][Full Text] [Related]
35. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
Avgil Tsadok M; Jackevicius CA; Rahme E; Humphries KH; Pilote L
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):593-9. PubMed ID: 26508666
[TBL] [Abstract][Full Text] [Related]
36. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy.
Fosbol EL; Wang TY; Li S; Piccini J; Lopes RD; Mills RM; Klaskala W; Thomas L; Roe MT; Peterson ED
Am Heart J; 2013 Nov; 166(5):864-70. PubMed ID: 24176442
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
38. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
39. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
Loffredo L; Perri L; Violi F
Dig Liver Dis; 2015 May; 47(5):429-31. PubMed ID: 25732432
[TBL] [Abstract][Full Text] [Related]
40. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Chang HY; Zhou M; Tang W; Alexander GC; Singh S
BMJ; 2015 Apr; 350():h1585. PubMed ID: 25911526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
